Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283155243> ?p ?o ?g. }
- W4283155243 endingPage "2181" @default.
- W4283155243 startingPage "2172" @default.
- W4283155243 abstract "This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC). Additionally, clinical value of the RAS/BRAF mutation status in circulating cell-free DNA (ccfDNA) was evaluated; this evaluation was measured independently of the protocol treatment. Eligible patients with RAS wild-type mCRC who had received the first-line panitumumab plus FOLFOX treatment were recruited and administered continuous panitumumab combined with FOLFIRI. Progression-free survival (PFS) at 6 months was the primary endpoint, with threshold and expected values of 35% and 50%, respectively. In total, 54 patients were enrolled between October 2017 and October 2019. The crude 6-month PFS rate was 37.0%, with a 4.8-month median PFS. The response rate and disease control rate were 16.7% and 50.0%, respectively. Notably, of the 54 participants, 17 showed RAS/BRAF mutations until the end of the protocol treatment and of the 22 patients with progressive disease as their best response, 10 possessed RAS/BRAF mutations in their plasma ccfDNA at baseline. The median PFS significantly differed among patients harboring tumors with BRAF and RAS mutations and those with wild-type tumors. In conclusion, our study failed to show the expected efficacy of the continuous panitumumab use in the second-line treatment. Liquid biopsy discriminated the duration of PFS according to the mutation status. The effectiveness of continuous treatment with panitumumab should be evaluated in patients with RAS/BRAF wild-type mCRC determined by liquid biopsy at the start of the second-line treatment." @default.
- W4283155243 created "2022-06-21" @default.
- W4283155243 creator A5001376020 @default.
- W4283155243 creator A5010610023 @default.
- W4283155243 creator A5012897883 @default.
- W4283155243 creator A5013344739 @default.
- W4283155243 creator A5017709438 @default.
- W4283155243 creator A5025670670 @default.
- W4283155243 creator A5026965702 @default.
- W4283155243 creator A5050479922 @default.
- W4283155243 creator A5052173467 @default.
- W4283155243 creator A5054543898 @default.
- W4283155243 creator A5058441704 @default.
- W4283155243 creator A5071060001 @default.
- W4283155243 creator A5071189253 @default.
- W4283155243 creator A5083303913 @default.
- W4283155243 creator A5086205123 @default.
- W4283155243 date "2022-07-05" @default.
- W4283155243 modified "2023-10-17" @default.
- W4283155243 title "Multicenter, single‐arm, phase <scp>II</scp> study of the continuous use of panitumumab in combination with <scp>FOLFIRI</scp> after <scp>FOLFOX</scp> for <scp>RAS</scp> wild‐type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell‐free <scp>DNA</scp>" @default.
- W4283155243 cites W2011349651 @default.
- W4283155243 cites W2015132197 @default.
- W4283155243 cites W2016920426 @default.
- W4283155243 cites W2052779140 @default.
- W4283155243 cites W2087809901 @default.
- W4283155243 cites W2098354753 @default.
- W4283155243 cites W2121847974 @default.
- W4283155243 cites W2133045939 @default.
- W4283155243 cites W2137591261 @default.
- W4283155243 cites W2143427907 @default.
- W4283155243 cites W2160373161 @default.
- W4283155243 cites W2330814896 @default.
- W4283155243 cites W2331318007 @default.
- W4283155243 cites W2529551829 @default.
- W4283155243 cites W2756716076 @default.
- W4283155243 cites W2889089744 @default.
- W4283155243 cites W2900337696 @default.
- W4283155243 cites W2902728680 @default.
- W4283155243 cites W3087758700 @default.
- W4283155243 cites W3088925649 @default.
- W4283155243 cites W3166878791 @default.
- W4283155243 cites W3182019035 @default.
- W4283155243 cites W3183441630 @default.
- W4283155243 cites W3208855266 @default.
- W4283155243 cites W4210808495 @default.
- W4283155243 doi "https://doi.org/10.1002/ijc.34184" @default.
- W4283155243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35723084" @default.
- W4283155243 hasPublicationYear "2022" @default.
- W4283155243 type Work @default.
- W4283155243 citedByCount "1" @default.
- W4283155243 countsByYear W42831552432022 @default.
- W4283155243 crossrefType "journal-article" @default.
- W4283155243 hasAuthorship W4283155243A5001376020 @default.
- W4283155243 hasAuthorship W4283155243A5010610023 @default.
- W4283155243 hasAuthorship W4283155243A5012897883 @default.
- W4283155243 hasAuthorship W4283155243A5013344739 @default.
- W4283155243 hasAuthorship W4283155243A5017709438 @default.
- W4283155243 hasAuthorship W4283155243A5025670670 @default.
- W4283155243 hasAuthorship W4283155243A5026965702 @default.
- W4283155243 hasAuthorship W4283155243A5050479922 @default.
- W4283155243 hasAuthorship W4283155243A5052173467 @default.
- W4283155243 hasAuthorship W4283155243A5054543898 @default.
- W4283155243 hasAuthorship W4283155243A5058441704 @default.
- W4283155243 hasAuthorship W4283155243A5071060001 @default.
- W4283155243 hasAuthorship W4283155243A5071189253 @default.
- W4283155243 hasAuthorship W4283155243A5083303913 @default.
- W4283155243 hasAuthorship W4283155243A5086205123 @default.
- W4283155243 hasConcept C104317684 @default.
- W4283155243 hasConcept C121608353 @default.
- W4283155243 hasConcept C126322002 @default.
- W4283155243 hasConcept C143065580 @default.
- W4283155243 hasConcept C143998085 @default.
- W4283155243 hasConcept C203092338 @default.
- W4283155243 hasConcept C207583985 @default.
- W4283155243 hasConcept C2776694085 @default.
- W4283155243 hasConcept C2776705615 @default.
- W4283155243 hasConcept C2778260052 @default.
- W4283155243 hasConcept C2778332735 @default.
- W4283155243 hasConcept C2778822529 @default.
- W4283155243 hasConcept C2779529041 @default.
- W4283155243 hasConcept C2780739268 @default.
- W4283155243 hasConcept C2780962732 @default.
- W4283155243 hasConcept C2781187634 @default.
- W4283155243 hasConcept C526805850 @default.
- W4283155243 hasConcept C535046627 @default.
- W4283155243 hasConcept C55493867 @default.
- W4283155243 hasConcept C71924100 @default.
- W4283155243 hasConcept C86803240 @default.
- W4283155243 hasConcept C90924648 @default.
- W4283155243 hasConceptScore W4283155243C104317684 @default.
- W4283155243 hasConceptScore W4283155243C121608353 @default.
- W4283155243 hasConceptScore W4283155243C126322002 @default.
- W4283155243 hasConceptScore W4283155243C143065580 @default.
- W4283155243 hasConceptScore W4283155243C143998085 @default.
- W4283155243 hasConceptScore W4283155243C203092338 @default.
- W4283155243 hasConceptScore W4283155243C207583985 @default.
- W4283155243 hasConceptScore W4283155243C2776694085 @default.
- W4283155243 hasConceptScore W4283155243C2776705615 @default.